Recently, at the High-Tech Park (Thu Duc City, Ho Chi Minh City), the groundbreaking ceremony for the construction of a blood biological product factory with a capacity of fractionating 600,000 liters of plasma per year took place, meeting the treatment needs of 250 million patients.

Thumb image 1.jpg
The factory has an investment capital of 2,700 billion VND and is expected to come into operation in 2026. Perspective photo: Binh Viet Duc

Speaking at the groundbreaking ceremony, Deputy Minister of Health Do Xuan Tuyen assessed that in recent years, the Vietnamese pharmaceutical industry has achieved many important achievements, basically providing enough medicine for medical examination, treatment and disease prevention and control. The Vietnamese pharmaceutical market has an annual growth rate of over 10%.

However, the domestic pharmaceutical industry mainly produces generic drugs and depends on raw materials. The number of high-tech drugs, specialized drugs for treating emerging diseases, serious diseases, especially biological products and biological drugs for medical examination and treatment is still limited.

Brother 2.jpg
Deputy Minister of Health Do Xuan Tuyen and the project investor at the groundbreaking ceremony for the factory producing biological products from plasma. Photo: Binh Viet Duc

According to reports from units, the demand for plasma and plasma fraction products for treatment needs in Vietnam is quite large. However, currently in Vietnam there is no factory producing biological products from plasma, so every year Vietnam still has to spend a large amount of foreign currency to import plasma fraction products to serve treatment needs.

We have raw materials but are completely dependent on foreign countries for finished products. The implementation of the project to build a factory to produce biological products from plasma is very necessary and meaningful at the present time. The project will make the most of and effectively use the extremely valuable plasma source to proactively and promptly produce products for treatment," Deputy Minister Do Xuan Tuyen shared.

Mr. Ngo Duc Binh - General Director of Binh Viet Duc Company Limited, the factory investor - said that after being put into operation, the project will make the most of the existing plasma resources to proactively and promptly produce essential biological products such as Albumin, Globulin... These drugs are specialized in serving the needs of treating serious diseases, while also supporting the prevention of dangerous epidemics such as measles and hand, foot and mouth disease.

Image 3.jpg
Mr. Ngo Duc Binh, General Director of Binh Viet Duc Company Limited, spoke at the ceremony. Photo: Binh Viet Duc

“Previously, the company collected plasma and sent it abroad for processing and then brought it back to Vietnam to treat people. After the factory in Vietnam is put into operation, the company will reduce costs, thanks to which the product price can be reduced by up to 2/3 compared to before,” he said.

The plant is expected to be operational in 2026, with a capacity to fractionate 600,000 liters of plasma per year. The project will not only meet the treatment needs of 250 million domestic patients but also aim to export to foreign markets.

Tu Uyen